International Journal of Gynecological Cancer最新文献

{"title":"The GOG Foundation and EVA/LACOG partnership: a collaborative strategic alliance for clinical trial execution.","authors":"Fernando Maluf, Robert L Coleman, Angélica Nogueira-Rodrigues, Bradley J Monk, Glauco Baiocchi, Kathleen N Moore, Andréia Cristina de Melo, David M O'Malley, Graziela Z Dal Molin, Leslie M Randall, Gonzalo Giornelli, Brian Slomovitz, René Pareja, Bhavana Pothuri, Ramez N Eskander, Gustavo Werutsky, Thomas J Herzog","doi":"10.1016/j.ijgc.2025.101991","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101991","url":null,"abstract":"<p><p>The collaborative efforts between GOG and LACOG are aimed at advancing clinical oncology research through strategic global partnerships, particularly related to the conduct of clinical trials. Herein, we provide the framework of this relationship addressing key operational components including establishing a shared Publication Policy. In addition, this initiative seeks to standardize contributions, recognize authorship fairly, and ensure compliance with agreed protocols. Emphasis is placed on critical practices like study design, data interpretation, manuscript development, and intellectual review. The Policy considers the roles of individual scientists, institutional sponsors, and contributors while ensuring transparency and authenticity in scientific communication. This collaborative approach underscores the importance of collective expertise in addressing global challenges in oncology and fostering innovation through multi-institutional cooperation. The manuscript outlines the processes for critical review, approval, and publication, ensuring credibility in the dissemination of scientific findings to the community. These frameworks aim to promote inclusivity, equitable representation, and the advancement of oncology knowledge.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101991"},"PeriodicalIF":4.1,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging data gaps before adopting the prognostic nutritional index in gynecologic oncology.","authors":"Xiyin Yang, Xiaoyan Wang","doi":"10.1016/j.ijgc.2025.101995","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101995","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101995"},"PeriodicalIF":4.1,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a prognosis model for PARP inhibitor therapies based on multiple genomic alterations associated with homologous recombination deficiency in ovarian cancer.","authors":"Tong Shu, Fan Yang, Lin Gao, Jinhua Zhou, Chao Zhang, Youguo Chen, Hong Zheng, Jundong Li","doi":"10.1016/j.ijgc.2025.101987","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101987","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to develop a high-performance prognostic model to predict poly(ADP-ribose) polymerase inhibitor (PARPi) treatment outcomes in patients with ovarian cancer.</p><p><strong>Methods: </strong>This was a retrospective cohort study. Inclusion criteria were high-grade serous or endometroid carcinoma, clear cell carcinoma with platinum-sensitive disease (>6 months without progression from the end of platinum) or platinum-responsive disease eligible for front-line PARPi therapy. All collected samples underwent OncoWES-HRD analysis, with an Homologous recombination deficiency (HRD) score threshold set at 39. We performed LASSO regression analysis to develop a predictive model for assessing the effectiveness of PARPi treatment in patients with ovarian cancer. The data were analyzed using R software.</p><p><strong>Results: </strong>We collected primary tumors from 221 Chinese patients with ovarian cancer, of whom 99 patients with high-grade serous ovarian carcinoma received PARPi treatment. Based on the HRD score threshold, 144 patients were classified as HRD-positive and 77 as HRD-negative. We found that the HRD-positive group had higher mutation frequencies of ANKHD1 and MUC16 compared to the HRD-negative group. Furthermore, biomarkers such as clonal mutations, BRCA mutations, high indel burden, and high loss-of-heterozygosity were associated with notably higher HRD scores and longer progression-free survival. Using HRD genomic features, we established a LASSO regression-based risk score model for predicting PARPi treatment outcomes. This model showed promising performance compared to other HRD assessments (the OncoWES-HRD score and the OncoWES-HRD and BRCA metrics), with a higher area under the curve and significantly longer progression-free survival (p< .05) in both training and test cohorts.</p><p><strong>Conclusions: </strong>We developed a novel prognostic model that can predict PARPi treatment outcomes, offering a valuable tool for identifying patients who may benefit from PARPi therapy in ovarian cancer. However, the model needs further validation.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 9","pages":"101987"},"PeriodicalIF":4.1,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Free-floating trophoblastic cyst in chemo-resistant gestational trophoblastic neoplasm.","authors":"Chia-Yi Lee, Ying-Cheng Chiang","doi":"10.1016/j.ijgc.2025.101985","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101985","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 8","pages":"101985"},"PeriodicalIF":4.1,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preclinical activity of sacituzumab govitecan in TROP2-positive low-grade serous ovarian cancer patient-derived xenograft models.","authors":"Victoria M Ettorre, Cem Demirkiran, Stefania Bellone, Na Niu, Natalia Buza, Namrata Sethi, Tobias Max Philipp Hartwich, Luca Palmieri, Alessandro D Santin","doi":"10.1016/j.ijgc.2025.101988","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101988","url":null,"abstract":"<p><strong>Objective: </strong>Low-grade serous ovarian cancer is a rare epithelial ovarian cancer subtype characterized by high resistance to chemotherapy and an indolent disease course. The development of novel, effective, targeted treatments for recurrent, chemotherapy-resistant low-grade serous ovarian cancer remains an unmet medical need. We evaluated trophoblast cell-surface antigen 2 (TROP2) expression in a cohort of patients with low-grade serous ovarian cancer and assessed the preclinical activity of sacituzumab govitecan, an antibody-drug conjugate targeting TROP2, in vivo using a patient-derived xenograft (PDX) model.</p><p><strong>Methods: </strong>TROP2 expression was evaluated in 26 patients with low-grade serous ovarian cancer using immunohistochemistry. The efficacy of sacituzumab govitecan was assessed in vivo in severe combined immunodeficiency mice using a TROP2-positive low-grade serous ovarian cancer PDX model established from a patient with disease resistant to chemotherapy, aromatase inhibitors, and MEK inhibitors.</p><p><strong>Results: </strong>TROP2 expression was observed in all low-grade serous ovarian cancer cases, with 21 of 26 (81%) samples demonstrating moderate to strong expression. In vivo studies in mice demonstrated that sacituzumab govitecan significantly inhibited tumor growth in a chemotherapy-, aromatase inhibitor-, and MEK inhibitor-resistant low-grade serous ovarian cancer PDX model compared to control animals treated with vehicle/saline (p < .0001). Median survival for control mice was 25 days, while it was not reached by the end of the experiment (day 50) in animals treated with sacituzumab govitecan.</p><p><strong>Conclusion: </strong>TROP2 is a novel biomarker highly expressed in low-grade serous ovarian cancer. Sacituzumab govitecan may represent a potentially effective new treatment option for patients with low-grade serous ovarian cancer progressing after standard treatment modalities. Further clinical trials in low-grade serous ovarian cancer treated with sacituzumab govitecan are warranted.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 9","pages":"101988"},"PeriodicalIF":4.1,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mesonephric-like adenocarcinoma of the ovary: features of a rare and aggressive entity associated with endometriosis.","authors":"Francesco Mezzapesa, Susanna Giunchi, Antonio De Leo, Dondi Giulia, Stella Di Costanzo, Lucia Genovesi, Dario De Biase, Pierandrea De Iaco, Anna Myriam Perrone","doi":"10.1016/j.ijgc.2025.101990","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101990","url":null,"abstract":"<p><strong>Objective: </strong>Mesonephric-like adenocarcinoma is a rare, aggressive ovarian cancer subtype, newly classified by the World Health Organization in 2020. This study examines the clinical, ultrasound, pathological features, and survival outcomes of ovarian mesonephric-like adenocarcinoma.</p><p><strong>Methods: </strong>This observational, prospective, single-center study included patients with ovarian mesonephric-like adenocarcinoma treated between January 2020 and December 2023. Clinical data and ultrasound findings were collected. Ultrasound examinations were performed according to the International Ovarian Tumor Analysis guidelines and qualitatively described in correlation with pathological findings. Histopathological evaluation was conducted based on the 2020 World Health Organization classification. Progression-free survival and overall survival were calculated from the time of diagnosis to recurrence or death.</p><p><strong>Results: </strong>Among 467 patients with ovarian cancer treated at our center, 14 (3.0%) were diagnosed with ovarian mesonephric-like adenocarcinoma, with a mean age of 60 ± 8 years. Ultrasound commonly showed unilateral solid lesions (57.2%) with moderate-to-strong blood flow, heterogeneous echogenicity, and hyperechoic \"cotton candy\" regions. Most patients (57.1%) had International Federation of Gynecology and Obstetrics stage III to IV disease; 78.5% underwent upfront surgery, achieving complete cytoreduction in 92.8%. Pathology revealed mesonephric-like adenocarcinoma alone in 44.4% and mixed histotypes in 55.6% (endometrioid, mucinous, or high-grade serous components), with endometriosis in 64.2%. K-RAS mutations were present in all cases. Median progression-free survival was 17.5 months (IQR 13.5-35.9), with 57.1% experiencing recurrence, mostly as peritoneal metastases. Median overall survival was not reached, with one death recorded.</p><p><strong>Conclusions: </strong>Mesonephric-like adenocarcinoma is a rare yet aggressive ovarian cancer strongly associated with endometriosis and characterized by K-RAS mutation. Unique ultrasound features, such as \"cotton candy\" hyperechoic regions, may assist in early recognition and pre-surgical diagnosis.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101990"},"PeriodicalIF":4.1,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and prognosis of rhabdomyosarcoma in the female reproductive system: a population-based analysis using SEER data.","authors":"Xinyan Gao, Yan Kong, Ying Ning, Zhumei Cui, Ke Lei, Tian Tian","doi":"10.1016/j.ijgc.2025.101989","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101989","url":null,"abstract":"<p><strong>Objective: </strong>Rhabdomyosarcoma of the female reproductive system is rare, and as a result, management strategies are unclear. In this study, we categorized rhabdomyosarcoma based on location (cervical, uterine, vulvovaginal) and analyzed prognostic factors to guide individualized treatment.</p><p><strong>Methods: </strong>Data from the Surveillance, Epidemiology, and End Results database (2000-2021) were used to identify patients with cervical, uterine, and vulvovaginal rhabdomyosarcoma. Multivariate Cox regression identified prognostic factors, and Kaplan-Meier analysis assessed overall survival and disease-specific survival.</p><p><strong>Results: </strong>For cervical rhabdomyosarcoma (n = 76), radical surgery improved disease-specific survival (91.9% vs 62.8%, p = .005), but conservative surgery was sufficient for patients aged <49 years, with a tumor diameter <4 cm, or with the embryonal subtype. In uterine rhabdomyosarcoma (n = 253), the embryonal subtype showed better overall survival (62.3% vs 23%, p < .0001) and disease-specific survival (65.9% vs 31%, p < .0001), especially for tumors ≤14 cm. For vulvovaginal rhabdomyosarcoma (n = 60), no survival differences were observed between local and radical surgery in patients aged <16 years or with tumors <8 cm. Adjuvant chemotherapy in cervical rhabdomyosarcoma has been shown to enhance the overall survival rate of patients undergoing radical surgery; however, radiotherapy appears to diminish their overall survival outcomes. In the case of uterine rhabdomyosarcoma of the embryonic subtype, chemotherapy concurrently improves both overall and disease-specific survival rates, while radiotherapy does not demonstrate a significant impact. For vulvovaginal rhabdomyosarcoma, chemotherapy is effective in improving the overall survival rate among non-surgical patients, whereas radiotherapy shows no effect on the survival outcomes across all subgroups.</p><p><strong>Conclusions: </strong>Conservative treatment is suitable for young patients with cervical rhabdomyosarcoma who have small tumors or the embryonal subtype, while radical surgery benefits the overall population. Embryonal uterine rhabdomyosarcoma has better outcomes, and young patients with vulvovaginal rhabdomyosarcoma of the embryonal subtype can undergo local surgery. For these 3 sites, chemotherapy is indispensable, while radiotherapy should be administered with caution.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 9","pages":"101989"},"PeriodicalIF":4.1,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"To cut or not to cut (completely): navigating the surgical sweet spot.","authors":"Heng-Cheng Hsu, Pedro T Ramirez","doi":"10.1016/j.ijgc.2025.101998","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101998","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 8","pages":"101998"},"PeriodicalIF":4.1,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three-dimensional image of uterine transposition.","authors":"Ester Miralpeix, Gemma Mancebo","doi":"10.1016/j.ijgc.2025.101984","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101984","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101984"},"PeriodicalIF":4.1,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding the workforce of clinical trial investigators committed to gynecologic cancer research: the GOG Foundation, Inc's Scholar Career Development Award and New Investigator Program.","authors":"Angeles Alvarez Secord, Ronald D Alvarez, Leslie M Randall, Robert S Mannel, David G Mutch, Michelle N Small, Robert L Coleman, Bradley J Monk, Kathleen N Moore, Larry J Copeland, Thomas J Herzog","doi":"10.1016/j.ijgc.2025.101982","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101982","url":null,"abstract":"<p><strong>Objective: </strong>Training and supporting early-career investigators are essential for developing a resilient and competent clinical research workforce in gynecologic oncology. To address persistent gaps in mentorship, protected time, funding, and leadership pathways, the Gynecologic Oncology Group Foundation, Inc (GOG-F) launched two-tiered development programs: the GOG-F New Investigator Program and the GOG-F Scholar Career Development Award. This 5-year evaluation reports academic, leadership, accrual, and funding outcomes.</p><p><strong>Methods: </strong>Annual structured electronic surveys were administered to all participants and queried committee membership, protocol involvement, clinical trial accrual, publications, abstracts, and grant activity. Mentor evaluations and participant testimonials were also collected. Descriptive statistics were used to summarize productivity metrics.</p><p><strong>Results: </strong>The 2019 cohort consisted of 10 Scholars and 36 New Investigators, comprising 37 females and 9 males. Participants identified as Asian (n = 9), non-Hispanic Puerto Rican (n = 1), White (n = 35), with 1 participant not reporting. Collectively, awardees held 107 committee roles, led 33 trials as (co-)principal investigators, and enrolled 3179 patients. Scholarly output included 516 peer-reviewed publications and 321 abstracts from Scholars, and 563 publications and 486 abstracts from New Investigators. Grant funding totaled $150.43 million, comprising $100.87 million (92 grants) from Scholars and $49.57 million (124 grants) from New Investigators. Two New Investigators advanced to Scholar status. The overall return on investment was $48.18 per $1.00 invested.</p><p><strong>Conclusions: </strong>The GOG-F Scholar Career Development Award has demonstrated strong success in cultivating clinical trial leaders through structured mentorship and protected research time. The New Investigator Program has effectively fostered early-career engagement, with demonstrable academic and leadership advancement. Together, these programs offer a scalable model for strengthening the gynecologic oncology research workforce and addressing gaps in clinical trial leadership.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101982"},"PeriodicalIF":4.1,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144617376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}